Forest Labs should do very well next year. Look for new 52 wk highs, based on improving margins of existing products, the introduction of Synaptin (once approved), and greater excitement for their next big antidepressant drug which will compete with prosac and other SSRI (selective seritonin reuptake inhibitors) drugs. Synaptin, which is under FDA approval now, should be a huge contributor to the bottom line. It'll be the only drug approved for Alztimers that works at the level of AcH receptors, which are believed to play an important role in the function of neurons, esp. those in the brain.